摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2-(喹啉-4-基)甲氧基苯基)-N-(3-三氟甲基苯基)-1,3,4-恶二唑-2-胺 | 1043593-34-5

中文名称
5-(2-(喹啉-4-基)甲氧基苯基)-N-(3-三氟甲基苯基)-1,3,4-恶二唑-2-胺
中文别名
——
英文名称
5-(2-(quinolin-4-yl)methoxyphenyl)-N-(3-trifluoromethylphenyl)-1,3,4-oxadiazol-2-amine
英文别名
5-[2-(quinolin-4-ylmethoxy)phenyl]-N-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-amine
5-(2-(喹啉-4-基)甲氧基苯基)-N-(3-三氟甲基苯基)-1,3,4-恶二唑-2-胺化学式
CAS
1043593-34-5
化学式
C25H17F3N4O2
mdl
——
分子量
462.431
InChiKey
GZGLHVLVVGRNMM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    34
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    73.1
  • 氢给体数:
    1
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    4-(氯甲基)喹啉 、 2-(5-(3-三氟甲基苯基氨基)-1,3,4-恶二唑-2-基)苯酚 在 potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以27%的产率得到5-(2-(喹啉-4-基)甲氧基苯基)-N-(3-三氟甲基苯基)-1,3,4-恶二唑-2-胺
    参考文献:
    名称:
    EP2128156
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY
    申请人:Honda Takahiro
    公开号:US20100016354A1
    公开(公告)日:2010-01-21
    The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; R a represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring; a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R 1 represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R 2 and R 2 ′, the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.
    本发明涉及由式(I)表示的化合物或其盐。在式(I)中,环A表示苯环,噻吩环或吡啶环;R表示氢原子,卤素原子,烷基或烷氧基;环B表示吡啶环,嘧啶环或喹啉环;环C表示苯环,吡啶环,喹啉环或异喹啉环;X和Y,相同或不同,表示氧原子或硫原子,但X是硫原子且Y是氧原子的情况除外;R1表示氢原子,卤素原子,氨基,环烷基氨基,烷基羰基氨基,烷氧羰基氨基,烷基氨基甲酰基或非芳香族杂环基;而R2和R2',相同或不同,表示氢原子,卤素原子,烷基,卤代烷基或卤代烷氧基。
  • Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
    申请人:Santen Pharmaceutical Co., Ltd.
    公开号:US08063034B2
    公开(公告)日:2011-11-22
    The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring; a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R1 represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R2 and R2′, the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.
    本发明涉及由式(I)所表示的化合物或其盐。在式(I)中,环A表示苯环、噻吩环或吡啶环;Ra表示氢原子、卤素原子、烷基或烷氧基;环B表示吡啶环、嘧啶环或喹啉环;环C表示苯环、吡啶环、喹啉环或异喹啉环;X和Y,相同或不同,表示氧原子或硫原子,但排除X为硫原子且Y为氧原子的情况;R1表示氢原子、卤素原子、氨基、环烷基氨基、烷基羰基氨基、烷氧羰基氨基、烷基氨基甲酰基或非芳香族杂环基;R2和R2',相同或不同,表示氢原子、卤素原子、烷基、卤代烷基或卤代烷氧基。
  • NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY
    申请人:Santen Pharmaceutical Co., Ltd
    公开号:EP2128156A1
    公开(公告)日:2009-12-02
    The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B represents a pyridine ring, a pyrimidine ring, or a quinoline ring; the ring C represents a benzene ring, a pyridine ring, a quinoline ring, or an isoquinoline ring; X and Y, the same or different, represent an oxygen atom or a sulfur atom, with the proviso that the case X is a sulfur atom and Y is an oxygen atom be excluded; R1 represents a hydrogen atom, a halogen atom, an amino group, a cycloalkylamino group, an alkylcarbonylamino group, an alkyloxycarbonylamino group, an alkylaminocarbonyl group, or a non-aromatic heterocyclic group; and R2 and R2', the same or different, represent a hydrogen atom, a halogen atom, an alkyl group, a halogeno-alkyl group, or a halogeno-alkoxy group.
    本发明涉及式(I)所代表的化合物或其盐类。在式 (I) 中,环 A 代表苯环、噻吩环或吡啶环;Ra 代表氢原子、卤素原子、烷基或烷氧基;环 B 代表吡啶环、嘧啶环或喹啉环;环 C 代表苯环、吡啶环、喹啉环或异喹啉环;X 和 Y 相同或不同,代表氧原子或硫原子,但不包括 X 为硫原子而 Y 为氧原子的情况;R1 代表氢原子、卤素原子、氨基、环烷基氨基、烷基羰基氨基、烷氧基羰基氨基、烷基氨基羰基或非芳香杂环基团;R2 和 R2'相同或不同,代表氢原子、卤素原子、烷基、卤代烷基或卤代烷氧基。
  • US8063034B2
    申请人:——
    公开号:US8063034B2
    公开(公告)日:2011-11-22
  • EP2128156
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多